scholarly journals SAT0477 A TWO-YEAR LONGITUDINAL STUDY COMPLETION, LONGITUNEAL STUDY, THE DIFFERENCE IN BONE LOSS IN PATIENTS WITH EROSIVE AND NON-EROSIVE HAND OSTEOARTHRITIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1195.2-1195
Author(s):  
K. Pavelka ◽  
L. Šenolt ◽  
O. Sleglova ◽  
J. Baloun ◽  
O. Růžičková
Keyword(s):  
Bone Mineral Density ◽  
Longitudinal Study ◽  
Lumbar Spine ◽  
Bone Loss ◽  
Bone Mineral ◽  
Hand Osteoarthritis ◽  
Mineral Density ◽  
Erosive Disease ◽  
Femur Neck ◽  
American College Of Rheumatology

Background:Hand osteoarthritis (OA) and its more severe subset erosive hand OA are common causes of pain and morbidity. Some metabolic factors were suggested to be implicated in erosive disease. Few studies investigated differences in systemic bone loss between erosive and non-erosive hand OA.Objectives:To compare the change of bone mineral density (BMD) between patients with erosive and non-erosive hand OA in a two-year longitudinal study.Methods:Consecutive patients with symptomatic HOA fulfilling the American College of Rheumatology (ACR) criteria were included in this study. Erosive hand OA was defined by at least one erosive interphalangeal joint. All patients underwent clinical assessments of joint swelling and radiographs of both hands. DEXA examination of lumbar spine, total femur and femur neck was performed at the baseline and after two years.Results:Altogether, 141patients (15 male) with symptomatic nodal HOA were included in this study and followed between April 2012 and January 2019. Out of these patients, 80 had erosive disease after two years. The disease duration (p<0.01) was significantly higher in patients with erosive compared with non-erosive disease at baseline.Osteoporosis (T-score <-2.5 SD) was diagnosed in 12.5% (9/72) of patients with erosive hand OA and in 8.06% (5/57) of patients with non-erosive hand OA at baseline. BMD was significantly lowered in patients with erosive compared with non-erosive disease at baseline (lumbar spine: 1.05g/cm2 vs. 1.13 g/cm2, p<0.05, total femur: 0.90 g/cm2 vs. 0.97 g/cm2, p<0.01 and femur neck: 0.86 g/cm2 vs. 0.91, p<0.05). T-scores of lumbar spine (-0.96 vs. -0.41 SD, p<0.05), total femur (-0.69 vs. -0.33 SD, p<0.05) and femur neck (-1.14 vs. -0.88 SD, p<0.05) were also significantly lowered in patients with erosive compared with non-erosive disease.Two years, the BMD remained also significantly lowered in patients with erosive compared with non-erosive disease (lumbar spine: 1.05g/cm2 vs. 1.14 g/cm2, p<0.05, total femur: 0.92 g/cm2 vs. 0.97 g/cm2, p<0.05 and femur neck: 0.86 g/cm2 vs. 0.91, p<0.05), which was in agreement with the finding for T-scores of lumbar spine (-1.05 vs. -0.39 SD, p<0.05), total femur (-0.74 vs. -0.34 SD, p<0.01) and femur neck (-1.07 vs. -0.72 SD, p<0.01).Conclusion:These results suggest that patients with erosive hand OA are at higher risk for the development of general bone loss. Over two years patients with erosive disease had significant lower bone mineral density at all measured sites.References:[1]This work was supported by the project AZV no. 18-00542 and MHCR No. 023728.Acknowledgments:Project AZV no. 18-00542 and MHCR No. 023728Disclosure of Interests:Karel Pavelka Consultant of: Abbvie, MSD, BMS, Egis, Roche, UCB, Medac, Pfizer, Biogen, Speakers bureau: Abbvie, MSD, BMS, Egis, Roche, UCB, Medac, Pfizer, Biogen, Ladislav Šenolt: None declared, Olga Sleglova: None declared, Jiří Baloun: None declared, Olga Růžičková: None declared

scholarly journals Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss

2008 ◽  
Vol 68 (3) ◽  
pp. 373-376 ◽  
Author(s):  
C A Wijbrandts ◽  
R Klaasen ◽  
M G W Dijkgraaf ◽  
D M Gerlag ◽  
B L F van Eck-Smit ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Bone Mineral Density ◽  
Lumbar Spine ◽  
Bone Loss ◽  
Disease Activity ◽  
Bone Mineral ◽  
Joint Disease ◽  
Mineral Density ◽  
Femur Neck ◽  
Adalimumab Therapy

Objective:To explore the effects of anti-tumour necrosis factor (TNF)α antibody therapy on bone mineral density (BMD) of the lumbar spine and femur neck in patients with rheumatoid arthritis (RA).Methods:A total of 50 patients with active RA (DAS28⩾3.2) who started adalimumab (40 mg subcutaneously/2 weeks) were included in an open label prospective study. All patients used stable methotrexate and were allowed to use prednisone (⩽10 mg/day). The BMD of the lumbar spine and femur neck was measured before and 1 year after start of treatment.Results:Disease activity at baseline (28-joint Disease Activity Score (DAS28)) and disease duration were inversely correlated with femoral neck BMD and lumbar spine BMD (p<0.05). Mean BMD of lumbar spine and femur neck remained unchanged after 1 year of adalimumab therapy (+0.3% and +0.3%, respectively). Of interest, a beneficial effect of prednisone on change in femur neck BMD was observed with a relative increase with prednisone use (+2.5%) compared to no concomitant prednisone use (−0.7%), (p = 0.015).Conclusion:In contrast to the progressive bone loss observed after conventional disease-modifying antirheumatic drug therapy, TNF blockade may result in an arrest of general bone loss. Consistent with previous observations, the data also suggest that the net effect of low-dose corticosteroids on BMD in RA may be beneficial, possibly resulting from their anti-inflammatory effects.

scholarly journals The Relationship Between Bone Mineral Density and Type 2 Diabetes in Obese Children and Adolescents at the Time of Initial Diagnosis

2018 ◽  
Vol 51 (01) ◽  
pp. 42-46
Author(s):  
Hae Lee ◽  
Jong Yoon ◽  
Kyu Park ◽  
Jung Lim ◽  
Jin Hwang
Keyword(s):  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Lumbar Spine ◽  
Children And Adolescents ◽  
Bone Mineral ◽  
Tanner Stage ◽  
Mineral Density ◽  
Femur Neck ◽  
Z Scores

AbstractLong-term effects of type 2 diabetes mellitus (T2D) on bone health remain unclear. The objective of this study was to assess the possible association of bone mineral density (BMD) at multiple sites with T2D after correcting for several potential confounders such as age, sex, Tanner stage, and BMI known to affect BMD in adolescents with newly developed T2D. In this cross-sectional study, 17 children and adolescents with T2D and 59 age, sex, and BMI-matched controls were included. All subjects underwent dual-energy X-ray absorptiometry to measure regional and whole-body composition with Lunar Prodigy at the time of initial diagnosis. A BMD Z-score was calculated using data from healthy Korean children and adolescents after adjusting for height-for-age. The mean age of all subjects was 12.9±2.4 years (range, 8.3–18.3 years). BMDht Z-scores for lumbar spine and total body after adjusted for age, sex, BMI SDS, and Tanner stage were not significantly different between patients and controls. However, BMDht Z-scores for femur neck and bone mineral apparent density (BMAD) Z-scores of lumbar spine were significantly lower in T2D patients than those in healthy controls. HOMA-IR or HbA1c was not associated with BMDht Z-scores at multiple sites. BMDht Z-scores at multiple sites except femur neck in adolescents with newly developed T2D were similar to those in obese controls after adjustment for potential confounders.

Annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized placebo-controlled trial

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 4515-4515 ◽  
Author(s):  
M. D. Michaelson ◽  
H. Lee ◽  
D. S. Kaufman ◽  
P. W. Kantoff ◽  
J. Finkelstein ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Mineral Density ◽  
Lumbar Spine ◽  
Zoledronic Acid ◽  
Bone Loss ◽  
Bone Mineral ◽  
Gnrh Agonist ◽  
Gonadotropin Releasing Hormone ◽  
Mineral Density ◽  
Total Hip

4515 Background: Gonadotropin-releasing hormone (GnRH) agonists decrease bone mineral density (BMD) and increase fracture risk in men with prostate cancer. Zoledronic acid (4 mg IV every 3 months) increases BMD in GnRH agonist treated men. Intermittent zoledronic acid (4 mg IV once annually) increases BMD in postmenopausal women with osteoporosis but the efficacy of the annual treatment schedule in hypogonadal men is unknown. Methods: In a 12-month open-label study, men with nonmetastatic prostate cancer (n = 44) who were receiving a GnRH agonist were assigned randomly to zoledronic acid (4 mg IV × 1) or placebo. BMD of the posteroanterior lumbar spine and total hip were measured by dual energy x-ray absorptiometry at baseline and month 12. Serum N-telopeptide, a marker of osteoclast activity, was measured every 3 months. Results: Mean (± SE) BMD of the posteroanterior lumbar spine increased by 4.0 ± 0.9 in men treated with zoledronic acid and decreased by 3.1 ± 0.9 percent in men who received placebo (P < 0.001 for between-group comparison). BMD of the total hip decreased by 0.7 ± 0.6 percent in men treated with zoledronic acid and decreased by 1.9 ± 0.7 percent in men who received placebo (P = 0.005). Compared to placebo, zoledronic acid significantly decreased serum N-telopeptide throughout the 12-month study (P < 0.05). Conclusions: In men receiving a GnRH agonist for prostate cancer, a single treatment of zoledronic acid significantly increased bone mineral density of the total hip and spine at 12 months. Annual zoledronic acid may provide a convenient and effective strategy to prevent bone loss in hypogonadal men. This study was supported in part by Novartis Oncology and by the Prostate Cancer Foundation. [Table: see text]

Bone mineral density of the lumbar spine in very-low-birth-weight infants: a longitudinal study

2000 ◽  
Vol 159 (3) ◽  
pp. 215-218 ◽  
Author(s):  
H. Ichiba ◽  
H. Shintaku ◽  
M. Fujimaru ◽  
C. Hirai ◽  
Y. Okano ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Longitudinal Study ◽  
Birth Weight ◽  
Lumbar Spine ◽  
Low Birth Weight ◽  
Bone Mineral ◽  
Very Low Birth Weight ◽  
Mineral Density ◽  
Low Birth Weight Infants

Brisk Walking Reduces Calcaneal Bone Loss in Post-Menopausal Women

1997 ◽  
Vol 92 (1) ◽  
pp. 75-80 ◽  
Author(s):  
Katherine Brooke-Wavell ◽  
Peter R. M. Jones ◽  
Adrianne E. Hardman
Keyword(s):  
Bone Mineral Density ◽  
Lumbar Spine ◽  
Bone Loss ◽  
Femoral Neck ◽  
Bone Mineral ◽  
Brisk Walking ◽  
Mineral Density ◽  
Control Subjects ◽  
Menopausal Women ◽  
Post Menopausal

1. This study examined the influence of brisk walking on skeletal status in post-menopausal women. 2. Subjects were 84 healthy women aged 60–70 years who were previously sedentary and at least 5 years post-menopausal. Subjects were randomly assigned to walking (n = 43) and control (n = 41) groups. Walkers followed a 12-month, largely unsupervised programme of brisk walking. The bone mineral density of the lumbar spine, femoral neck and calcaneus and broadband ultrasonic attention of the calcaneus were measured at baseline and after 12 months. 3. Forty control subjects and 38 walkers completed the study. Walkers built up to 20.4 ± 3.8 min/day (mean ± SD) of brisk walking. Body mass increased in control subjects relative to walkers [mean change (SE) ± 0.9 (0.3) and −0.1 (0.3) kg respectively; P = 0.04]. Predicted maximum oxygen uptake increased in walkers by 2.1 (0.9) ml min−1 kg−1 (P = 0.02). Bone mineral density in the lumbar spine and calcaneus fell in control subjects [–0.005 (0.004) and −0.010 (0.004) g/cm2, respectively] but not in walkers [+0.006 (0.004) and +0.001 (0.004) g/cm2]. The difference in response between groups was significant in the calcaneus (P = 0.04) but not in the lumbar spine (P = 0.08). Mean femoral neck bone mineral density did not change significantly in either group, although changes in walkers were related to the amount of walking completed (r = 0.51, P = 0.001). The change in broadband ultrasonic attenuation of the calcaneus differed between groups [control subjects, −3.7 (0.8); walkers, −0.7 (0.8) dB/MHz; P = 0.01]. 4. Walking decreased bone loss in the calcaneus and possibly in the lumbar spine. It also improved functional capacity and enabled walkers to avoid the increase in body mass seen in control subjects.

RELATIONSHIP BETWEEN SERUM OC AND SCTX WITH BONE MINERAL DENSITY IN PREDICTING BONE LOSS AND TREATING FOR POSTMENOPAUSAL OSTEOPOROSIS WOMEN OVER 45 YEARS OLD WITH FOSAMAX PLUS THERAPY

2017 ◽  
pp. 126-231
Author(s):  
Van Duc Tran ◽  
Van An Le ◽  
Hai Thuy Nguyen
Keyword(s):  
Bone Mineral Density ◽  
Lumbar Spine ◽  
Bone Loss ◽  
Prospective Study ◽  
Key Words ◽  
Postmenopausal Osteoporosis ◽  
Negative Correlation ◽  
Mineral Density ◽  
Cross Sectional ◽  
Femur Neck

Backgrounds: Serum OC and ssCTX are correlated with BMD and have early changes under antiresorptive therapies. This study was aimed to find correlations between serum OC, sCTX and BMD changes in women over 45 and evaluated early changes of the two markers in postmenopausal osteoporotic women with Fosamax plus therapy. Materials and Methods: Cross-sectional and prospective study. 142 women over 45 were tested for serum OC and sCTX and determined BMD at lumbar spine and femur neck. 37 postmenopausal osteoporotic women of the group were treated with Fosamax plus therapy. Results: OC and sCTX showed negative correlation with BMD of lumbar spine and femur neck in all of women over 45. The correlation between sCTX and BMD of femur neck was not significant. The lowest values of OC and sCTX to predict bone loss in non-osteoporotic women were 14.46ng/ml (ss = 76.1%, sp = 40%) and 396.25pg/ml (ss = 66%, sp = 52%). The decreasing rates of serum OC and sCTX after 3 and 6 months with Fosamax plus therapy were 41.6%, 55% (p ˂ 0.0001) and 78.3%, 72% (p ˂ 0.0001), respectively. Slow increasing rates of BMD at two sites were 4.2% (p ˂ 0.001) and 3.6% (p ˃ 0.05), irrespectively. Conclusions: OC and sCTX were inversely correlated to BMD of lumbar spine and femur neck in all of women over 45. The lowest values of OC and sCTX to predict bone loss in non-osteoporotic women were 14.46ng/ml and 396.25pg/ml. Serum OC và sCTX decreased early in comparision to BMD improvement in postmenopausal osteoporotic women with Fosamax plus therapy. Key words: oC, sCTX, postmenopausal osteoporotic women, Fosamax plus

Effect of anastrozole on bone mineral density: 5-year results from the ’Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 511-511 ◽  
Author(s):  
R. E. Coleman
Keyword(s):  
Bone Mineral Density ◽  
Lumbar Spine ◽  
Bone Loss ◽  
Bone Mineral ◽  
Treatment Effect ◽  
Mineral Density ◽  
Total Hip ◽  
Slowing Down ◽  
Significant Difference ◽  
Hip Bmd

511 Background: Since reporting the 1- and 2-year results from the ATAC trial bone sub-protocol, 68-month analysis results from the main ATAC trial have shown that, for postmenopausal women with invasive primary breast cancer, adjuvant treatment with anastrozole results in superior efficacy and tolerability compared with tamoxifen. Here we report 5-year bone mineral density (BMD) results from the monotherapy arms (anastrozole, n=81; tamoxifen, n=86) of the bone sub-protocol. Methods: Lumbar spine and total hip BMD were assessed by dual-energy X-ray absorptiometry at baseline and after 1, 2, and 5 years. Results: The median percentage changes in BMD at 1, 2, and 5 years, respectively, are shown in the table . Percentage changes in BMD from baseline to 5 years showed a statistically significant difference in favor of tamoxifen for both lumbar spine (treatment effect [percentage decrease of BMD on anastrozole relative to tamoxifen] −8.1; 95% confidence intervals [CI] −10.1, −6.1; p<0.0001) and total hip (treatment effect −7.4; 95% CI −9.6, −5.3; p<0.0001). For patients with data at baseline, 2, and 5 years, the rate of loss of lumbar spine BMD in the anastrozole group was significantly less from 2 to 5 years than from baseline to 2 years (mean difference in annual rate of change 0.0113, 95% CI 0.006, 0.017; p=0.0002), but there was no evidence of slowing down in the loss of total hip BMD. Five patients with osteopenia at baseline developed osteoporosis on treatment with anastrozole (4) or tamoxifen (1). No patients with normal BMD at baseline became osteoporotic at 5 years. Conclusions: Significant bone loss occurred throughout the 5 years in the anastrozole group, although there appeared to be a slowing down of the rate of bone loss in years 2–5. Although no patients with normal BMD at baseline had become osteoporotic at 5 years, regular monitoring of BMD and bone protection strategies are likely to be required in patients receiving anastrozole in the presence of pre-existing osteopenia. [Table: see text] [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document